Filing Flows

Filing Flows › Aclaris Therapeutics (ACRS) › Next earnings date

Aclaris Therapeutics (ACRS) earnings: beat the estimate

Aclaris Therapeutics (ACRS) reported on Nov 5, 2026 and beat the EPS estimate: −$0.12 against −$0.16 (+25.8%). Revenue was $1.5M for Q3 2026, -55% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+25.8% vs estimate
Beat rate80%

The last report

Aclaris Therapeutics reported revenue of $1.5M for the third quarter 2026 (-55% Y/Y), net loss $18.5M: Licensing $1.2M, Contract research $300K. How it makes money → · Every quarter →

Aclaris Therapeutics: EPS against the estimate, last 5 reportsAclaris Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.14−$0.12Nov 25−$0.14−$0.16Feb 26−$0.16−$0.15May 26−$0.16−$0.15Aug 26−$0.16−$0.12Nov 26
Latest (Nov 26): Estimate −$0.16, Reported −$0.12.

Aclaris Therapeutics' latest quarter

Aclaris Therapeutics, Q3 2026: revenue $1.5M (-55% year over year), net loss $18.5M, operating cash flow −$24.1M. The chart follows the revenue to costs, profit and cash.

Questions

Did Aclaris Therapeutics beat earnings?

Aclaris Therapeutics (ACRS) reported on Nov 5, 2026 and beat the EPS estimate: −$0.12 against −$0.16 (+25.8%).

When does ACRS report earnings?

The next date is not set yet.

Does Aclaris Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.